Faddis, Veeva Systems SVP, sold $214,646 in shares

Jonathan Faddis, SVP, Gen. Counsel, Secretary at Veeva Systems Inc (NYSE:VEEV), sold 720 shares of Class A Common Stock on October 6, 2025, at a price of $298.12, totaling $214,646. The transaction occurred near Veeva’s 52-week high of $310.50, with the stock showing remarkable momentum, gaining over 46% in the past six months. According to InvestingPro analysis, the company maintains a "GREAT" financial health score.

Following the transaction, Faddis directly owns 7868 shares of the company’s Class A Common Stock.

The sale was executed under a Rule 10b5-1 trading plan adopted on December 19, 2024. Faddis also made a charitable gift of 5001 shares.

In other recent news, Veeva Systems has seen significant developments with multiple pharmaceutical companies committing to its Vault CRM platform. Bristol Myers Squibb announced its decision to implement Veeva’s AI-enhanced CRM system, aimed at improving engagement with healthcare practitioners. Similarly, Gilead Sciences has expanded its partnership with Veeva by adopting the Vault CRM for its commercial execution needs. These commitments from top pharmaceutical companies are part of the nine total commitments Veeva disclosed during its recent earnings call.

In related developments, BNP Paribas Exane reiterated its Outperform rating on Veeva Systems with a price target of $320.00, citing these customer wins as a positive indicator. Raymond James also maintained an Outperform rating with a $340.00 price target, following Veeva’s recent successes in the pharmaceutical sector. Meanwhile, Salesforce has secured AbbVie as its third top 20 pharmaceutical client for CRM solutions, joining previous wins with Pfizer and Takeda. These selections highlight Salesforce’s growing influence in the pharmaceutical industry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.